Donate

For Clinicians

  • Essential Resources

Supporting Healthcare Professionals in Early Diagnosis, Treatment Pathways, and Patient Care

Over 9,000 people are diagnosed with oesophageal cancer annually in the UK. Early diagnosis dramatically improves outcomes, from 5% to 70% five-year survival rates.

Contact
  • Essential Resources

Supporting Healthcare Professionals in Early Diagnosis, Treatment Pathways, and Patient Care

Over 9,000 people are diagnosed with oesophageal cancer annually in the UK. Early diagnosis dramatically improves outcomes – from 5% to 70% five-year survival rates.

Contact

The Clinical Challenge

“Gastric and oesophageal cancers are mostly diagnosed at a late stage when curative treatment might not be possible. There is a real need for early detection.” – Imperial College London research

The challenge is significant:

  • Less than 1/3 of patients diagnosed with early disease
  • 15% diagnosed after emergency admission have reduced treatment options
  • Long-term survival ~15% UK-wide

But evidence shows improvement is possible through systematic early detection strategies.

Reference Links:

Recognising the Early Signs

Research shows more than 80% of patients with gastro-oesophageal cancer report at least one red-flag symptom predictive of underlying cancer.

NICE Criteria for Urgent Investigation

Urgent direct access endoscopy (within 2 weeks) for:

  • New onset dysphagia (any age)
  • Weight loss + upper GI symptoms (aged 55+)
  • Upper abdominal mass consistent with stomach cancer

“All patients with new dysphagia, gastrointestinal bleeding, recurrent aspiration or emesis and weight loss and/or loss of appetite should undergo upper intestinal endoscopy” – ESMO Guidelines

Reference Links:

Evidence-Based Practice Standards

Current guidelines have evolved based on substantial new evidence. Key changes in NICE NG83 (2023 update) reflect improved understanding of optimal care pathways.

What the Evidence Shows:

  • Centralisation of services has reduced post-operative mortality
  • Specialist MDT approach improves outcomes
  • Early detection programs can significantly improve survival

 

Reference Links:

Barrett's Oesophagus Management

Barrett’s oesophagus is a pre-malignant condition where the normal lining of the lower oesophagus is replaced by columnar epithelium. It is the main precursor to oesophageal adenocarcinoma. Current guidelines emphasise risk-stratified surveillance rather than a one-size-fits-all approach.

Current Surveillance Guidance

The 2023 ESGE guideline (endorsed by BSG) and NICE NG231 now form the basis for Barrett’s management in the UK, replacing the BSG 2013/2015 guidelines:

Non-dysplastic Barrett’s:

  • Segment <3 cm: surveillance endoscopy every 5 years
  • Segment 3–10 cm: surveillance endoscopy every 3 years
  • Segment ≥10 cm: referral to a Barrett’s expert centre
  • Consider stopping surveillance if patient has reached age 75 at last surveillance endoscopy

Dysplastic Barrett’s:

  • Low-grade dysplasia (confirmed by expert GI pathologist): discuss endoscopic ablation therapy with specialist MDT, or 6-monthly surveillance if ablation not undertaken
  • High-grade dysplasia: MDT referral for endoscopic eradication therapy (resection of visible lesions followed by ablation)
  • Indefinite for dysplasia: optimise PPI therapy, repeat endoscopy in 3–6 months

 

Emerging Approaches: Cytosponge

The Cytosponge is a swallowable cell-collecting device showing promise as a less invasive alternative to endoscopy for Barrett’s surveillance and screening:

  • The device is swallowed in a dissolvable capsule, expands in the stomach, and collects cell samples when withdrawn
  • Samples are tested for TFF3 (trefoil factor 3), a biomarker for intestinal metaplasia, and can be assessed for p53 and cytological atypia
  • Early UK studies show that 77–90% of surveillance patients may not require endoscopy after Cytosponge assessment
  • The BEST2 and BEST3 trials have demonstrated feasibility in primary care settings, with a 10-fold increase in Barrett’s detection compared to usual care

 

While Cytosponge is not yet part of routine clinical practice, it is increasingly being used in pilot programmes, particularly where endoscopy capacity is limited. Larger prospective validation studies are ongoing.

Regional Variation

There is significant regional variation in Barrett’s surveillance practice across the UK. Factors include:

  • Differences in endoscopy capacity and waiting times
  • Local adoption of updated guidelines (some centres still following older BSG intervals)
  • Availability of expert GI pathology review for dysplasia grading
  • Access to specialist centres for endoscopic eradication therapy

Clinicians should be aware of their local protocols while referencing current national guidance.

Reference Links:

Treatment Pathways

NHS cancer network reorganisation has established specialist centres with improved outcomes:

  • Reduced variation in practice
  • Improved access to specialist care
  • Better coordination between centres

Multidisciplinary Team (MDT) Approach

NICE Recommendation: All patients with oesophago-gastric cancer should have access to an oesophago-gastric clinical nurse specialist through their MDT

Treatment Modalities Overview

Most patients with oesophageal cancer are treated with a combination of modalities rather than a single treatment. For squamous cell carcinoma, definitive chemoradiotherapy is often the primary approach. For adenocarcinoma, perioperative chemotherapy (or neoadjuvant chemoradiotherapy) combined with surgery is the standard of care for resectable disease. Single-modality treatment may be appropriate in selected cases, such as endoscopic resection for very early-stage disease or palliative radiotherapy for symptom relief.

Surgical Options:

  • Endoscopic mucosal resection or submucosal dissection for early disease
  • Oesophagectomy or oesophagogastrectomy for advanced localised disease

Non-surgical Treatments:

  • Chemotherapy before/after surgery or with radiotherapy
  • Immunotherapy and targeted drugs for advanced disease

Reference Links:

Patient Support Resources

NICE recommends providing patients with information in appropriate format to review in their own time after diagnosis discussions.

Available Resources:

  • Patient information leaflets
  • Treatment option explanations
  • Support group contact details
  • Nutritional guidance

Palliative Care Integration

Early palliative care referral is recommended for all patients with advanced or incurable oesophageal cancer. Research demonstrates that early integration of palliative care improves quality of life and may even extend survival.

For patients requiring palliative management, provide personalised information on:

  • Honest, sensitive discussions about prognosis (if the patient wishes)
  • Available treatment options and their aims – including palliative chemotherapy, immunotherapy, radiotherapy for symptom relief, and stenting for dysphagia
  • Nutritional support – specialist dietetic input, consideration of stents, PEG/RIG tubes, and liquid nutrition
  • Pain management – early referral to specialist palliative care for complex symptoms
  • Psychological support for patients and families – including referral to counselling, clinical psychology, and peer support services
  • Advance care planning – including preferred place of care and DNACPR discussions where appropriate
  • Sources of reliable information – Macmillan, Marie Curie, Cancer Research UK, and OCHRE’s own patient resources

 

The ROCS trial (Lancet Gastroenterology & Hepatology) demonstrated that for patients with oesophageal stents, holistic supportive care focused on quality of life delivered outcomes comparable to additional radiotherapy, with fewer treatment burdens. This reinforces the importance of shared decision-making and prioritising what matters to each patient.

 

Reference Links:

Quality Improvement Metrics

Key Performance Indicators

National audit data shows:

  • 30-day post-operative mortality has fallen year-on-year
  • 3-year survival rates have improved from ~33% to current levels through service reorganisation

Current Survival Outcomes:

  • Current 3-year survival: ~50% stomach tumours, ~45% oesophageal tumours when suitable for curative treatment
  • 30-day post-operative mortality: 1.7% oesophageal, 1.1% stomach cancer
  • Early diagnosis (mucosal layer): >70% 5-year survival
  • Advanced disease with metastases: ~5-7% 5-year survival

Reference Links:

Key Warning Signs

Need Immediate Support?

Helpful Links

Support Our Work

Your donation helps us provide vital support and fund research for better treatments.

Donate